The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”

Bell2Bell’s latest podcast features Setti Coscarella, CEO of TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF). During the briefing, Coscarella discussed the company’s alternative to cigarettes and vape products.

“TAAT is an alternative combustible cigarette. Basically, what we do is make a cigarette from a combination of different plants that does not include tobacco,” Coscarella explained. “One of the primary ingredients is hemp. What we have done is transform that hemp, so it behaves like tobacco when smoked. We created a product that is non-addictive, that still satiates smokers like a cigarette does and provides them with the experience and taste of a cigarette at a much more affordable price. From a value proposition, smokers will find our product to be significantly better than any cigarette on the market today.”

Bell2Bell’s latest podcast features Setti Coscarella, CEO of TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF). During the briefing, Coscarella discussed the company’s alternative to cigarettes and vape products.

“TAAT is an alternative combustible cigarette. Basically, what we do is make a cigarette from a combination of different plants that does not include tobacco,” Coscarella explained. “One of the primary ingredients is hemp. What we have done is transform that hemp, so it behaves like tobacco when smoked. We created a product that is non-addictive, that still satiates smokers like a cigarette does and provides them with the experience and taste of a cigarette at a much more affordable price. From a value proposition, smokers will find our product to be significantly better than any cigarette on the market today.”